Tissue engineering is a rapidly growing scientific field that uses cell and/or cell combinations with biomaterials and/or biologically active molecules to create, repair, and/or replace cells, tissues, and organs. It aids in the production of materials that closely resemble the body's native tissue/tissues. Current medicines have been revolutionized as a result of tissue engineering, and the quality of life for millions of patients has improved. TE, although its many promises, has a number of limitations; translating these concepts into reality appears to be a difficult undertaking. One of the barriers is the inability of artificial materials to match the natural characteristics of tissues. This problem could be solved via nanotechnology and tailored nanoparticle engineering. This problem could be solved via nanotechnology and tailored nanoparticle engineering. Nanoparticles are distinguished by their nanoscale dimension, which allows them to develop important physical and chemical properties that improve their performance and hence make them useful in a variety of applications. Nanoparticles have just lately been employed in TE in order to increase mechanical and biological performance. Nanoparticles have an advantage in TE because of their small size and high surface-to-volume ratio, which is equivalent to peptides and small proteins. They are quickly absorbed by cells due to their ability to diffuse across membranes.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Will be updated soon...
Vasiliki E Kalodimou, European University-Cyprus Ltd, Cyprus
Title : Will be updated soon...
Nagy Habib, Imperial College London, United Kingdom
Title : Will be updated soon...
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : Advanced 3D tissue models: Pioneering tools for investigating health and disease
Lucie Bacakova, Institute of Physiology of the Czech Academy of Sciences, Czech Republic
Title : Developing iPSC-derived 3D Outer Blood-Retinal Barrier Disease Models of Choroideremia for Gene Therapy Evaluation
Aradhana Kasimsetty, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), United States